Targeted Natural Killer (NK) Cell Based Adoptive Immunotherapy for the Treatment of Patients With Non-Small Cell Lung Cancer (NSCLC) After Radiochemotherapy (RCT)

Exclusion Criteria

• •Any severe heart disease or any severe concomitant disease (ECOG stage \> 2)
• •NSCLC patients (stage IIIA/B) eligible for initial surgery with a confirmed consent of an interdisciplinary tumorboard
• •Patients that show ALK positivity or an activating mutation of the EGFR-TK domain
• •Patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology
• •Receipt of immunosuppressive drugs including high dose systemic corticosteroids within 3 weeks before study entry. Low dose corticosteroids as they are a common treatment option for patients suffering from COPD are not an exclusion criterium